阿斯利康因心脏病药物晚期临床试验失败,成为富时100指数中跌幅最大的个股

路透中文
Jul 09
BUZZ-<a href="https://laohu8.com/S/AZN">阿斯利康</a>因心脏病药物晚期临床试验失败,成为富时100指数中跌幅最大的个股

7月9日 - ** 阿斯利康(AZN.L)股价一度暴跌9.6%至12,874便士;有望创下自2017年以来最惨淡的一天

** AZN成为富时100指数 .FTSE 中跌幅最大的个股,该指数下跌0.4%

** 该公司表示,其与Ionis(IONS.O)合作研发的神经疾病药物Wainua,在晚期临床试验中 (link) 未能达到降低心血管死亡率及心血管疾病复发率的主要目标

** 今年以来,AZN股价下跌6%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10